Table 3.
Antimicrobials usage and the 28-day survival rates in patients with bacteraemic pneumonia caused by biofilm-forming Acinetobacter baumannii.
| Main agents used | Patients, no. | APACHE II score | Patients, no. (%) | 28-Day survivors | ||
|---|---|---|---|---|---|---|
| Median (interquartile range) | Appropriate antimicrobial therapy | Combination antimicrobial therapy | 28-Day non-survivors | |||
| Anti-pseudomonal penicillinsa | 10 | 22 (16.53–0.75) | 5 (50.0) | 1 (10.0) | 7 (70.0) | 3 (30.0) |
| Anti-pseudomonal cephalosporinsb | 16 | 26 (17.25–30.25) | 4 (25.0) | 1 (7.1) | 6 (37.5) | 10 (62.5) |
| Anti-pseudomonal fluoroquinolonesc | 3 | 39 (20–39) | 0 (0) | 0 (0) | 3 (100.0) | 0 (0) |
| Anti-pseudomonal carbapenemsd | 12 | 29 (21.75–35.75) | 6 (50.0) | 1 (8.3) | 5 (41.7) | 7 (58.3) |
| Ampicillin/sulbactam or sulbactam | 6 | 36.5 (21.75–44) | 1 (16.7) | 3 (50.0) | 2 (33.3) | 4 (66.7) |
| Non-antipseudomonal β-lactamasese | 11 | 19 (13–33) | 0 (0) | 2 (18.2) | 4 (36.4) | 7 (63.6) |
*Data are the median (interquartile range) for continuous variables and number of cases (%) for categorical variables. APACHE II = Acute Physiologic and Chronic Health Evaluation II.
aPiperacillin, piperacillin/tazobactam and ticarcillin/clavulanate.
bCefoperazone, ceftazidime, cefepime and cefpirome.
cCiprofloxacin and levofloxacin.
dImipenem and meropenem.
ePenicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole and flomoxef.